Clinical trials: Influenza Vaccines
Influenza
QuickVue Influenza A+B Clinical Field Trial
A comparative study of different swab types used for collection of specimens for rapid inluenza testing
- Trial name
- NCT00491283
- Testing
- Swab Specimen Collection (QuickVue)
- Where
- Australia
- Sponsor
- Quidel Corporation
Influenza A, Influenza Type B
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
To establish the relative accuracy of the LIAISON® NES Flu A/B, RSV \& COVID-19 assay for viral nucleic acid targets from professionally collected or patient self-collected dry nasal (NS) swabs and to establish the relative…
- Conditions
- Influenza A, Influenza Type B, Coronavirus Disease 2019, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT06392451
- Testing
- LIAISON NES FLU A/B, RSV, & COVID-19, LIAISON PLEX Respiratory Flex Assay
- Where
- 4 sites in Australia
- Volunteers
- 1,000 people
- Sponsor
- DiaSorin Molecular LLC
Healthy Free-living Elderly
Effect of the Consumption of a Fermented Dairy Drink on the Immune Function
The purpose of this study is to determine whether the regular consumption of the active product enhances the immune function, in comparison to the control product.
- Trial name
- NCT01521182
- Testing
- 1-Fermented Dairy Product (test), 2-Milk-based non-fermented dairy product (control)
- Where
- Belgium
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Danone Global Research & Innovation Center
Influenza, Human
Efficacy Study With QIVc in Pediatric Subjects
This phase 3 clinical study is a randomized, observer-blind, multicenter study of QIVc versus a non-influenza vaccine in subjects 6 months though 47 months of age.
- Trial name
- NCT03932682
- Testing
- QIVc, Comparator
- Where
- 74 sites in Bangladesh, Bulgaria and 13 more
- Volunteers
- 5,723 people, healthy volunteers welcome
- Sponsor
- Seqirus
Flu, Cold
Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal
The common cold is a major cause of nasal obstruction and reaches children and adults two or more times a year. At the moment, there is no cure for the common cold, and therefore the reduction of symptoms is the focus of the…
- Conditions
- Flu, Cold, Allergic Disorder of Respiratory System
- Trial name
- NCT01533220
- Testing
- naphazoline hydrocloride, Naphazoline hydrocloride + Pheniramine Maleate + Panthenol
- Volunteers
- 132 people
- Sponsor
- EMS
Pandemic Influenza Disease
Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects
The present study aims to evaluate safety and immunogenicity of two doses, administered three weeks apart, of two influenza vaccines containing 7.5 micrograms or 15 micrograms of H5N1 influenza antigen, in non-elderly adult and…
- Trial name
- NCT00311480
- Testing
- Influenza vaccine surface antigen adjuvanted with MF59
- Where
- 4 sites in Italy
- Volunteers
- 520 people
- Sponsor
- Novartis
Influenza A, Influenza B
Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer
The objective of this study is to evaluate the clinical sensitivity and specificity of the Liat™ Influenza A/B \& RSV Assay and the Liat™ Influenza A/B Assay when used on the Liat Analyzer to detect the presence or absence of…
- Conditions
- Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT02067286
- Where
- 8 sites in United States
- Volunteers
- 1,642 people
- Sponsor
- IQuum, Inc.
Influenza, Human
The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)
The purpose of this study is to evaluate the safety, tolerance, and immunogenicity of MAS-1-Adjuvanted seasonal inactivated influenza vaccine (IIV) (MER4101) with hemagglutinin dose escalation compared to non-adjuvanted…
- Trial name
- MER4101 (NCT02500680)
- Testing
- MER4101, Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Nova Immunotherapeutics Limited
Pneumococcal Disease
Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately
- Trial name
- NCT04526574
- Testing
- Experimental 20-valent pneumococcal conjugate vaccine (20vPnC), Saline, Influenza vaccine
- Where
- 63 sites in United States
- Volunteers
- 1,796 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza, Acute Upper Respiratory Infection
Treatment of Influenza and ARVI in Children by Kagocel ®
This study examined the etiology of acute respiratory viral infections (ARVI) during the 2015-2016 season, evaluated the statistics of the incidence of influenza and ARVI in this period (epidemiology: severity of the disease and…
- Trial name
- NCT04651491
- Testing
- Kagocel
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Nearmedic Plus LLC
Influenza Type A, Influenza Type B
Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza
Currently, there is only one treatment which only need one single oral dose for influenza in children five years above (Baloxavir marboxil) in China.
- Trial name
- NCT06507813
- Testing
- ADC189 tablets, Baloxavir Marboxil tablets, ADC189 granules
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Jiaxing AnDiCon Biotech Co.,Ltd
Influenza
A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine
Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00505453
- Testing
- Fluviral®
- Where
- 2 sites in Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Seasonal Influenza
Yearly Strain Variation Study, 2010/2011
The purpose of the study is to verify the immunogenicity and tolerance of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2010/2011 season for yearly licensing application.
- Trial name
- NCT01157702
- Testing
- Inactivated influenza vaccine (split virus, Vero cell-derived)
- Where
- Austria
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model
FLU-v is a broad spectrum influenza vaccine that targets regions conserved among multiple influenza strains. FLU-v adjuvanted with Montanide ISA-51 was shown to be safe in previous trials.
- Trial name
- NCT03180801
- Testing
- adjuvanted FLU-v, Influenza challenge
- Where
- United Kingdom
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Influenza
A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers
The purpose of the study is to assess the efficacy and safety of CSL's 2009/2010 formulation of the Enzira vaccine.
- Trial name
- NCT00888381
- Testing
- Inactivated Influenza Vaccine (2009 / 2010 formulation)
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Cardiovascular Diseases, Atrial Fibrillation
A Digital Flu Intervention for People With Cardiovascular Conditions
A 6-month prospective, digital randomized controlled trial targeting approximately 49,000 individuals to evaluate the effectiveness of an influenza vaccination intervention during influenza season for people with cardiovascular…
- Conditions
- Cardiovascular Diseases, Atrial Fibrillation, Abnormal Heart Rhythms, Cardiac Arrest
- Trial name
- CardioFlu (NCT04584645)
- Testing
- Targeted digital intervention
- Where
- United States
- Volunteers
- 49,138 people
- Sponsor
- Evidation Health
Influenza
Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Anhui/1/2013 (H7N9) administered at 3 dose levels in adjuvanted (SE) rHA formulations…
- Trial name
- PSC26 (NCT02464163)
- Testing
- Panblok, rHA adjuvant
- Where
- 9 sites in United States
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza, Human
A Pilot Study to Evaluate the Safety and Immunogenicity of Low Dose Flu Vaccines
The purpose of this study is to determine whether low dose flu vaccines delivered with microneedles into the skin (intradermally) are effective.
- Trial name
- NANOVAX (NCT00558649)
- Testing
- Flu Vaccine (FLUARIX®)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- NanoPass Technologies Ltd
Influenza, Human
Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults
This study evaluates the safety, tolerability and immunogenicity of IL-YANG quadrivalent vaccine versus IL-YANG trivalent vaccine after a single intramuscular administration in healthy Korean males and females 19 to < 65 years of…
- Trial name
- NCT02480998
- Testing
- IL-YANG Flu Vaccine QIV 0.5mL, IL-YANG Flu Vaccine TIV 0.5mL
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Influenza
Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects
Based on pre-clinical trial data and principle of GCP, the objective of phase I clinical trial is to evaluate safety and immunogenicity of Pan-flu vaccine, an inactivated whole virion H5N1 vaccine with aluminium hydroxide…
- Trial name
- NCT00356798
- Testing
- an inactivated whole virion H5N1 vaccine, adjuvanted
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.